Sabra Health Care REIT (NASDAQ:SBRA) Q1 Earnings Beat Signals Accelerating Operational Momentum

By – Last update:

Quotes Stocks Mentioned

Article Mentions:

Sabra Health Care REIT (NASDAQ:SBRA) delivered a first-quarter earnings beat that sent a clear signal to the market: the company’s operational momentum is accelerating. The healthcare REIT reported results on April 29, 2026, that comfortably exceeded analyst expectations on both revenue and earnings, driven by strong performance in its managed senior housing portfolio and robust investment activity.

Q1 2026 Earnings: A Clear Beat on Revenue and Profit

For the first quarter, Sabra reported total revenues of $221.8 million, significantly outpacing the consensus estimate of $207.3 million. On the earnings front, the company posted Normalized Adjusted Funds From Operations (Normalized AFFO) of $0.39 per diluted share, well above the analyst forecast of $0.17 per share.

Key per-share metrics for the quarter included:

  • Net Income: $0.16
  • Funds From Operations (FFO): $0.37
  • Normalized FFO: $0.38
  • Normalized AFFO: $0.39

The strong revenue figure was driven by a surge in resident fees and services, which jumped to $116.7 million from $77.4 million in the prior year’s quarter, reflecting the growth of Sabra’s managed senior housing operations.

Market Reaction and Price Action

Despite the strong headline numbers, the after-market performance of the stock was muted, showing a fractional decline of approximately 1.7%. This suggests that while the earnings beat was substantial, some of the positive news may have already been priced into the stock following strong gains over the past month (up 5.5%). Investors are likely digesting the details of the company’s financing activities, including the use of forward sale agreements.

Key Operational Highlights from the Press Release

Several metrics stood out in the quarterly report, reinforcing the strength of Sabra’s operating model:

  • Portfolio Coverage: EBITDARM coverage ratios reached new highs across all asset classes. Skilled nursing/transitional care coverage hit 2.46x, while behavioral health and specialty hospitals performed exceptionally well at 4.00x.
  • Managed Senior Housing Growth: Same property managed senior housing Cash NOI surged 14.4% year-over-year, driven by margin expansion across the portfolio.
  • Investment Activity: Sabra has been highly active on the acquisition front. In Q1, the company closed on $96 million in investments at an average initial cash yield of 8.3%. Since the quarter ended, total investments closed year-to-date have reached $206.1 million on a gross basis, with an estimated initial cash yield of 8.0%.
  • Forward Pipeline: The company reported it has been awarded an additional $200 million in managed senior housing and skilled nursing investments, most of which are expected to close in the second quarter.
  • Balance Sheet: Net Debt to Adjusted EBITDA stood at a healthy 5.04x. The board declared a quarterly cash dividend of $0.30 per share.

Outlook and Guidance

Crucially, Sabra reiterated its full-year 2026 guidance. While the company did not provide a specific numerical earnings target in the release, the reaffirmation provides stability for investors. This is particularly notable given the heavy investment activity already underway.

For context, analysts have estimated the following for the remainder of the year:

  • Q2 2026 Sales Estimate: $208.5 million
  • Q2 2026 Revenue Estimate: $185.1 million
  • Full Year 2026 Sales Estimate: $833.97 million

The company’s robust pipeline and strong coverage ratios suggest it is well-positioned to meet or exceed these expectations, provided the economic backdrop for senior housing and skilled nursing remains supportive.

For a detailed breakdown of Sabra’s historical earnings performance and to track future projections against analyst estimates, visit the Earnings Page and the Analyst Ratings Page.

Disclaimer: This article is for informational purposes only and does not constitute investment advice. Past performance is not indicative of future results. Always conduct your own research or consult with a qualified financial advisor before making investment decisions.